Acetylcarnitine
Trials 28
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT02696512 | Mar 2016 → Mar 2017 | brain injury | International Brain Research Foundation | Unknown | No outcome recorded |
| Phase 1/2 | NCT01537549 | Sep 2010 → Sep 2013 | progressive supranuclear palsy | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 1/2 | NCT00592488 | Aug 2006 → Aug 2009 | infectious disease with sepsis | Vanderbilt University | Completed | No outcome recorded |
| Phase 29 trials · 1 missed | ||||||
| Phase 2 | NCT05601479 | Nov 2022 → Dec 2024 | chemotherapy-induced neuropathy | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT05616000 | Aug → Nov 2022 | male infertility | Khyber Medical University Peshawar | Completed | No outcome recorded |
| Phase 2 | NCT02598622 | Sep 2009 → May 2012 | chemotherapy-induced neuropathy | Indiana University | Terminated | No outcome recorded |
| Phase 2 | NCT01054768 | Aug 2009 → Apr 2013 | sickle cell disease | UCSF Benioff Children's Hospital Oakland | Completed | No outcome recorded |
| Phase 2 | NCT00751205 | Aug 2008 → Feb 2010 | ovarian carcinoma, prostate cancer | Bayer | Completed | Missed primary |
| Phase 2 | NCT00555841 | Mar 2007 → Sep 2008 | breast cancer | Sigma-Tau Research, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT00581919 | Feb 2004 → Dec 2010 | plasma cell myeloma | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 2 | NCT00393770 | Feb 2004 → Oct 2006 | type 2 diabetes mellitus | Mario Negri Institute for Pharmacological Research | Completed | No outcome recorded |
| Phase 2 | NCT00225160 | Nov 2003 → ? | HIV infectious disease, peripheral neuropathy | Royal Free Hampstead NHS Trust | Unknown | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT06126315 | Mar 2025 → Apr 2027 expected | amyotrophic lateral sclerosis | Mario Negri Institute for Pharmacological Research | Recruiting | No outcome recorded |
| Phase 2/3 | NCT02141035 | Sep 2015 → Jun 2017 | carpal tunnel syndrome | University of Alberta | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01379976 | Apr 2011 → Oct 2014 | non-small cell lung carcinoma | Mario Negri Institute for Pharmacological Research | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00984750 | Apr 2008 → May 2012 | hypertensive disorder, type 2 diabetes mellitus | Mario Negri Institute for Pharmacological Research | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT02955706 | Apr 2016 → Sep 2018 | Alzheimer disease | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT04346862 | Jan 2016 → Jun 2020 | cognitive impairment with or without cerebellar ataxia | Hanmi Pharmaceutical Company Limited | Unknown | No outcome recorded |
| Phase 4 | NCT01524861 | Dec 2011 → Dec 2015 | Tako-tsubo cardiomyopathy, sympathetic nervous system disorder | University of Campania Luigi Vanvitelli | Completed | No outcome recorded |
| Phase 4 | NCT01913964 | Oct 1997 | — | University of Catania | Completed | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT07660081 | Dec 2025 → Jul 2026 | obesity disorder, osteoarthritis, type 2 diabetes mellitus | Khyber Medical University Peshawar | Completed | No outcome recorded |
| — | NCT05767515 | Jul 2023 → Feb 2024 | female infertility, polycystic ovary syndrome | Khyber Medical University Peshawar | Completed | No outcome recorded |
| — | NCT06042738 | Mar → Nov 2021 | male infertility | Ondokuz Mayıs University | Completed | No outcome recorded |
| — | NCT01921868 | Aug 2013 → Jun 2017 | Friedreich ataxia | University of South Florida | Unknown | No outcome recorded |
| — | NCT01223768 | Jul 2002 → Dec 2005 | hepatic encephalopathy | University of Catania | Completed | No outcome recorded |
| — | NCT01223742 | Jun 2002 → Dec 2006 | hepatic encephalopathy | University of Catania | Completed | No outcome recorded |
| — | NCT01223729 | Apr 2002 → Nov 2005 | hepatic encephalopathy | University of Catania | Completed | No outcome recorded |
| — | NCT00050271 | ? → Jan 2007 | HIV infectious disease, peripheral nervous system disorder | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Comparator or background therapy9 trials | ||||||
| Phase 2 | NCT04113889 Comparator | Oct 2019 → Jan 2020 | polycystic ovary syndrome | Khyber Medical University Peshawar | Completed | No outcome recorded |
| Phase 2 | NCT01471652 Comparator | Mar 2012 → Feb 2013 | myalgic encephalomeyelitis/chronic fatigue syndrome | Columbia University | Withdrawn | No outcome recorded |
| Phase 2 | NCT00719706 Comparator | Aug 2008 → May 2011 | bipolar depression | Mclean Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02173132 Comparator | Apr 2010 → Nov 2013 | occupation-related stress disorder | University of Catania | Completed | No outcome recorded |
| Phase 3 | NCT01909557 Comparator | Jan 2010 → Dec 2011 | — | University of Catania | Completed | No outcome recorded |
| Phase 3 | NCT01526564 Comparator | Aug 2008 → Apr 2011 | sensory peripheral neuropathy | Lee's Pharmaceutical Limited | Completed | No outcome recorded |
| Phase 4 | NCT01695317 Comparator | Apr 2013 → Jul 2014 | migraine disorder | Norwegian University of Science and Technology | Completed | No outcome recorded |
| — | NCT02999958 Comparator | Dec 2016 → May 2018 | — | Vitrolife | Completed | No outcome recorded |
| — | NCT02971878 Comparator | Nov 2016 → Feb 2018 | — | Fertilitetscentrum AB | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 43 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Acetylcarnitine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01379976 ↗ |
| Known as | Acetyl carnitine hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1697733 ↗ |
| Known as | Acetyl-L-carnitine | “A Randomised Double Blinded Placebo Controlled Pilot Study to Evaluate the Safety and Efficacy of Acetyl L Carnitine in Combination With Antiretroviral Therapy for the...” NCT00225160 ↗34“food supplement containing 2000 mg L-carnitine, 2000 mg fructose, 932 mg acetyl L-carnitine, 225 mg vitamin C, 115 mg citric acid, 50 mg coenzyme Q10, 14 mg zinc, 115 µg...” NCT06042738 ↗ “A recent study found that a primed constant infusion of acetyl-L-carnitine (ALC) may increase glucose utilization in type 2 diabetic patients, possibly restoring the glycogen...” NCT00984750 ↗ “Carnitine is involved in lipids and carbohydrates metabolism and acetyl-L-carnitine (ALC), an intramitochondrial carrier of acylic group, may modulate cell fuel substrate utilization.” NCT00393770 ↗ “Acetyl L-Carnitine is an isomer synthesized by two amino acids lysine and methionin mainly distributed among skeletal and cardiac muscles in mammals (8, 9).” NCT04113889 ↗ “Battery of nutraceuticals provided through a 12-week schedule including: Acidophilus, Alpha-Lipoic Acid, Acetyl L-Carnitine,” NCT02696512 ↗ “Acetyl-L-carnitine (ALC) offers neuroprotective benefits and improves mitochondrial energetics and function.” PMID 21310833 ↗ Feb 2011 “Acetyl-L-Carnitine will be given in dose of 1000mgBD Daily for 30 infertile female PCOS patients” NCT05767515 ↗ “Oral Acetyl-l-carnitine (ALC) in Non-anemic Potentially Curable Breast Cancer Subjects” NCT00555841 ↗ “Acetyl-L-Carnitine (ALCAR) 1.5 g PO BID days 1-21” NCT00581919 ↗ “2. Acetyl L-carnitine: oral capsule bid” NCT01471652 ↗ |
| Known as | Acetyl-L-carnitine (ALC) | “Acetyl-L-carnitine (ALC)” NCT02999958 ↗ |
| Known as | Acetyl-L-Carnitine Hydrochloride | “Acetyl-L-Carnitine Hydrochloride enteric-coated tablets” NCT01526564 ↗ |
| Known as | Acetylcarnitine hydrochloride, l- | ChEMBL registry synonym — accepted as the source's own label CHEMBL1697733 ↗ |
| Known as | ALC | “This study was designed to compare the endocrine and metabolic parameters as well as subjective and objective measures of stress in women with PCOS before and after treatment...” PMID 34047916 ↗ May 202110“The purpose of this study is to determine if acetyl-L-carnitine (ALC) reduces pain, numbness, and tingling in the feet and legs of patients with nucleoside reverse...” NCT00050271 ↗ “A recent study found that a primed constant infusion of acetyl-L-carnitine (ALC) may increase glucose utilization in type 2 diabetic patients, possibly restoring the glycogen...” NCT00984750 ↗ “Human embryos will be cultured in media that contains 3 antioxidants (Acetyl-L-carnitine (ALC), N-acetyl-L-cysteine (NAC) and α-lipoic acid (ALA)) that can be found in the in...” NCT02971878 ↗ “Carnitine is involved in lipids and carbohydrates metabolism and acetyl-L-carnitine (ALC), an intramitochondrial carrier of acylic group, may modulate cell fuel substrate utilization.” NCT00393770 ↗ “Acetyl-L-carnitine (ALC) offers neuroprotective benefits and improves mitochondrial energetics and function.” PMID 21310833 ↗ Feb 2011 “Oral Acetyl-l-carnitine (ALC) in Non-anemic Potentially Curable Breast Cancer Subjects” NCT00555841 ↗ “Studies suggest that acetyl-L-carnitine (ALC) may prevent chemotherapy-induced PN.” PMID 24105751 ↗ Oct 2013 “In addition, subjects will receive Acetyl-L-Carnitine (ALC) 1000 mg tid.” NCT00751205 ↗ “Acetyl-L-Carnitine (ALC) Hydrochloride Enteric-coated Tablets” NCT01526564 ↗ “ALC (acetylcarnitine) plus cisplatin-containing chemotherapy” NCT01379976 ↗ |
| Known as | ALCAR | “Phase II/III multicenter, randomized, double-blind, placebo-controlled trial on acetyl-L-carnitine (ALCAR) in subjects living with amyotrophic lateral sclerosis (ALS).” NCT06126315 ↗2“treatment with two proven mitochondrial enhancers, acetyl-L-carnitine (ALCAR) and α-lipoic acid (ALA)” NCT00719706 ↗ “Acetyl-L-carnitine (ALCAR) is involved in lipid transport, vital for mitochondrial function.” PMID 27079660 ↗ Apr 2016 |
| Known as | L-acetyl carnitine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01537549 ↗ |
| Known as | Oristar acc | ChEMBL registry synonym — accepted as the source's own label CHEMBL1697733 ↗ |
| Modality | Small molecule | “Carnitine a quaternary ammonium compound made in the body from lysine and methionine and is available in an active ( L) and an inactive (D ) form.” NCT05767515 ↗ |
| Route | Oral | “24-week oral acetyl-L-carnitine (1 g twice daily) therapy” PMID 19620516 ↗ Jul 2009 |